No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1	azacitidine oral Sensitive: A1 - Approval azacitidine oral Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
No biomarker	Juvenile Myelomonocytic Leukemia	No biomarker	Juvenile Myelomonocytic Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
EZH2 mutation	Acute Myelogenous Leukemia	EZH2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B
TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
ASXL1 mutation	Acute Myelogenous Leukemia	ASXL1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2

DNMT inhibitor

DNMT inhibitor

Associations(133)

Associations
(133)